Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Ted Love, MD, Joins Gilead Sciences' Board of Directors

Business Wire February 1, 2024

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

Business Wire January 30, 2024

From the Margins: Gilead's Book Uniquely Captures What It's Like To Be Marginalized by Disease

Accesswire January 30, 2024

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Business Wire January 29, 2024

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024

Business Wire January 23, 2024

Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer

Accesswire January 23, 2024

Gilead Provides Update on Phase 3 EVOKE-01 Study

Business Wire January 22, 2024

Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer

Accesswire January 16, 2024

Gilead Pays Tribute to Patient Advocacy Work: Cara's Story

Accesswire January 10, 2024

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

Accesswire January 3, 2024

U.S. FDA Approves Label Update for Kite's Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Business Wire December 21, 2023

Gilead Sciences to Present at Upcoming Investor Conference

Business Wire December 21, 2023

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

PR Newswire December 20, 2023

Gilead Supports World Health Organization To Bolster Public Health in Bangladesh

Accesswire December 19, 2023

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Business Wire December 19, 2023

Gilead's Legal Team Achieves Rigorous Diversity Certification

Accesswire December 12, 2023

Analyses of Kite's Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

Business Wire December 11, 2023

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite's Tecartus® in Patients With Aggressive Blood Cancers

Business Wire December 11, 2023

Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Business Wire December 11, 2023

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

Business Wire December 11, 2023